**PROMOTIONAL MATERIAL INTENDED FOR PATHOLOGISTS ONLY** Prescribing information and adverse event reporting information for Keytruda (pembrolizumab) can be found via the following external links: **Prescribing information (Great Britain)**, **Prescribing information (Northern Ireland)** 





## **OVERVIEW OF PD-L1 TESTING<sup>1,2</sup>**

Antibody	28-8	22C3	SP142	SP263
Instrument and detection systems required	Dako Autostainer Link 48 EnVision FLEX visualization system	Dako Autostainer Link 48 EnVision FLEX visualization system	Ventana BenchMark Ultra OptiView DAB IHC Detection Kit and OptiView Amplification Kit	Ventana BenchMark Ultra OptiView DAB IHC Detection Kit
Product for which assay was validated	nivolumab*	pembrolizumab	atezolizumab▼	durvalumab▼†
Associated scoring algorithm	TPS	CPS	IC	TC, IC

CONCORDANCE BETWEEN ASSAYS BY SCORING ALGORITHM AND CUTOFFS

# HODGSON ET AL. 2018

- ▶ Assays tested/compared: Ventana SP263, Ventana SP142, Dako 22C3²
- ▶ Fleiss' kappa ICC analysis showed excellent reliability between SP263 and 22C3 (ICC=0.929) in TC staining²
  - ▶ SP142 TC staining was lower with moderate correlation (ICC 0.525–0.619)<sup>2</sup>
- ► The reliability of IC staining was lower compared to TC staining (ICC 0.519–0.866)²

<sup>\*</sup> PD-L1 testing is not required.

<sup>†</sup> Durvalumab is not currently licensed for UC in the UK.

**PROMOTIONAL MATERIAL INTENDED FOR PATHOLOGISTS ONLY** Prescribing information and adverse event reporting information for Keytruda (pembrolizumab) can be found via the following external links: **Prescribing information (Great Britain)**, **Prescribing information (Northern Ireland)** 





## 2

## TRETIAKOVA ET AL. 2018

- ▶ Assays tested/compared: 22C3, 28-8, SP142³
- ▶ Pairwise concordance correlation coefficients between the three antibodies ranged from 0.76 to 0.88 for tumour cells and from 0.35 to 0.85 for immune cells³
  - ▶ In tumour cells, the highest agreement was reached between 22C3/28-8 (concordance correlation coefficient 0.88 (0.86–0.90), whereas the lowest agreement was seen between 22C3/SP142 0.76 (0.73–0.79), with the comparison of 28-8/SP142, 0.85 (0.83–0.87), falling between the two³
  - ▶ In immune cells, the highest agreement was reached between 22C3/28-8 (concordance correlation coefficient 0.85 (0.83–0.97), whereas the lowest agreement was seen between 22C3/SP142 0.35 (0.29–0.40), with the comparison of 28-8/SP142, 0.38 (0.32–0.43), also showing a low level of agreement³

# 3

### SCHWAMBORN ET AL. 2017

- ▶ Assays tested/compared: Ventana SP142, Ventana SP263, Dako 22C3, Dako 28-8<sup>4</sup>
- ▶ Retrospective allocation to binary cut-offs (1%, 5% and 10%) for IC and TC showed substantial or high Kappa agreement scores (0.6–0.8) for IC and TC between assays for each reader⁴
- ▶ High concordance rates across all assays were achieved between trained readers for scoring PD-L1 on IC and TC⁴

#### **SUMMARY**

Overall, the results found that all the assays showed reasonable concordance<sup>2–4</sup>

#### **FURTHER INFORMATION**

The platform independent test E1L3N (Cell Signalling Technologies) and the RNAscope assay were also tested, showing

good concordance with other assays<sup>2,3</sup>

Adverse events should be reported.

Reporting forms and information can be found at

https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple

App Store. Adverse events should also be reported to MSD (Tel: 0208 154 8000)

#### REFERENCES

- 1. Ionescu DN *et al. Curr Oncol.* 2018; 25(3): e209–e216.
- 2. Hodgson A *et al. Am J Surg Pathol.* 2018; 42(8): 1059–1066.
- 3. Tretiakova M *et al. Mod Pathol.* 2018; 31(4): 623–632.
- 4. Schwamborn K *et al.* Presented at EMSO 2017. Abstract 1175P.

#### **ABBREVIATIONS**

**CPS**, combined positive score **IC**. immune cells

 ${f ICC}$ , intraclass correlation coefficient

**PD-L1**, programmed death ligand-1

TC. tumour cells

**TPS**, tumour proportion score